Update on Current Phase III Clinical Trials in Melanoma

نویسندگان

  • Amy Q. Cao
  • Ming Yu Cao
چکیده

Melanoma is the deadliest form of skin cancer and responsible for 4% of all cancer deaths and 86% of skin cancer-related deaths in the United States (Losina et al., 2007). Melanoma is caused by malignant growth of the melanocytes, which are melanin-producing cells found in the skin’s epidermis, hair, and eyes. In melanoma, these cells undergo an uncontrollable cell growth that manifests in the skin, the nail bed, and sometimes although rarely in the eyes and mucous membrane (Garbe et al., 2010). Melanomas can be classified clinically into four major classes (Table 1). Most melanomas are superficially spreading malignant melanoma. Rare melanomas include amelanotic melanoma, splitzoid melanoma, desmoplastic melanoma, malignant blue nevus, ocular melanoma, and mucosa melanoma. Melanomas usually have an initial radial growth phase followed by a vertical growth phase. The radial growth is mostly intraepidermal, and is considered preinvasive or minimally invasive. In contrast, the vertical growth is invasion

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Characteristics of Clinical Trials in Iran: A Sample of 5000 Trials Registered in IRCT

Background and Objectives: A considerable number of clinical trials are conducted in Iran each year. Not much is known about the characteristics of them, this study aimed to investigate key characteristics of Iranian clinical trials.   Methods: All clinical trial protocols registered in IRCT until November 2013 were selected. Text mining techniques were used to extract information from data t...

متن کامل

Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.

Since their approval by regulatory agencies worldwide, the anti-PD-1 monoclonal antibodies (mAbs), as monotherapy or in combination with ipilimumab, have become the standard frontline therapy for advanced BRAF-wild-type melanoma and an eminent rival to targeted therapy in the first-line setting for unresectable BRAF-mutated melanoma. Mature survival data from randomized phase 3 trials have emer...

متن کامل

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update

At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant mel...

متن کامل

Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.

BACKGROUND Lung cancer is the most common cause of cancer-related death in the United States, yet traditional chemotherapy fails to provide long-term benefit for many patients. New approaches are needed to improve overall survival beyond the current standard of care. METHODS This review discusses recent clinical trials using immunotherapy techniques to treat both non-small cell lung cancer (N...

متن کامل

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012